LRP5L Inhibitors
LRP5L inhibitors are a variety of chemical compounds that function to dampen the activity of LRP5L, a protein involved as a co-receptor in the Wnt/β-catenin signaling pathway. The inhibitors accomplish this by primarily targeting and suppressing the Wnt/β-catenin pathway, thereby indirectly decreasing the functional activity of LRP5L. Compounds such as Quercetin, Niclosamide, Berberine, and IWR-1 function by inhibiting the Wnt/β-catenin signaling pathway. The signaling pathway is crucial to the functioning of LRP5L, hence its inhibition leads to decreased activity of LRP5L.
Other LRP5L inhibitors like XAV939, JW55, Calphostin C, CGP049090, FH535, KY02111, Wnt-C59, and ICG-001 work in a similar manner, disrupting the Wnt/β-catenin signaling pathway and thereby indirectly inhibiting LRP5L. For instance, XAV939 inhibits tankyrase, leading to the stabilization of Axin and thereby inhibiting the Wnt/β-catenin pathway. Similarly, JW55 functions by blocking the interaction of β-catenin with the transcription factor TCF within the Wnt/β-catenin pathway, indirectly inhibiting the role of LRP5L. Each of these inhibitors, through their unique mechanisms, leads to the inhibition ofthe Wnt/β-catenin signaling pathway, thus impacting the functional activity of LRP5L.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin is a flavonoid that can inhibit the Wnt/β-catenin pathway, in which LRP5L is a co-receptor. This can hamper the downstream signaling, leading to a decrease in the functional activity of LRP5L. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide is an anthelmintic drug that is known to inhibit Wnt/β-catenin signaling by promoting the degradation of β-catenin. This can attenuate LRP5L's function as it is dependent on this pathway. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $92.00 | 1 | |
Berberine is a bioactive alkaloid that can inhibit the Wnt/β-catenin signaling pathway, thereby indirectly inhibiting LRP5L which is involved in this pathway. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $135.00 | 19 | |
IWR-1 is a small molecule inhibitor that stabilizes the destruction complex in the Wnt/β-catenin pathway, leading to a decrease in the functional activity of LRP5L. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV939 inhibits tankyrase, which leads to the stabilization of Axin and the subsequent inhibition of the Wnt/β-catenin pathway, indirectly inhibiting LRP5L. | ||||||
JW 55 | 664993-53-7 | sc-364517 sc-364517A | 10 mg 50 mg | $172.00 $726.00 | ||
JW55 is an inhibitor that functions by blocking the interaction of β-catenin with the transcription factor TCF in the Wnt/β-catenin pathway, indirectly inhibiting LRP5L's role. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
Calphostin C inhibits the Wnt/β-catenin pathway by preventing the interaction between β-catenin and TCF. This can lead to LRP5L inhibition as it is involved in this pathway. | ||||||
Cercosporin | 35082-49-6 | sc-255013 | 5 mg | $459.00 | 1 | |
Cercosporin is a small molecule inhibitor that inhibits the Wnt/β-catenin pathway by preventing β-catenin's interaction with TCF, indirectly inhibiting LRP5L. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $182.00 $374.00 | 7 | |
FH535 is an inhibitor of the Wnt/β-catenin and PPAR signaling pathways. By inhibiting the Wnt/β-catenin pathway, it can indirectly inhibit LRP5L. | ||||||
KY02111 | 1118807-13-8 | sc-397043 sc-397043A | 5 mg 25 mg | $79.00 $336.00 | ||
KY02111 promotes the degradation of β-catenin by inhibiting Wnt signaling, leading to an indirect inhibition of LRP5L. | ||||||